Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 1, 2020

View Archived Issues

AP-1 and antidepressant action

Candida auris: mostly, nothing wrong

BeiGene and Singlomics sign license agreement for SARS-CoV-2-neutralizing antibody drug candidates

Immutep and Monash University receive grant from ARC to extend their LAG-3 project

FDA accepts IND application for phase IIa study of SPR-720

Discovery of novel HIF-PHD2 inhibitors for the treatment of anemia

First preclinical data presented for ATI-2173, a novel compound for treating HBV

French investigators patent new acetylcholinesterase reactivators

Results from first clinical trial of KB-174 in patients with well-compensated cirrhosis

Merck KGaA synthesizes new KIT mutant inhibitors

Ardelyx divulges glycyrrhetinic derivatives for hyperkalemia

Maruho identifies new BRD4 inhibitors

New TYK2 ligands presented by Ventyx Biosciences

Regulatory loop modulates innate-adaptive immune crosstalk in fever

Anti-vimentin monoclonal antibody hzVSF-v13 safe in phase I trial

HH-2853 enters first-in-human study for NHL and advanced solid tumors

Oxurion begins phase II study of THR-149 for DME

Phase III study of Kevzara in severely or critically ill COVID-19 patients misses primary endpoint

FDA clears Sound Pharmaceuticals to begin phase II studies with ebselen in COVID-19

FDA approves Xaracoll for acute postsurgical pain relief following open inguinal hernia repair

GSK and Vir begin phase II/III study of anti-SARS-CoV-2 monoclonal antibody VIR-7831

Prevail opens phase I/II study of PR-006 in frontotemporal dementia with progranulin mutations

European approval for Imfinzi as first-line treatment of extensive-stage small cell lung cancer

Embera begins phase II study of EMB-001 for cocaine use disorder

FDA clears IND for clinical development of OMS-906 for PNH